ArticleJAAD international2021
The global, regional, and national burden of fungal skin diseases in 195 countries and territories: A cross-sectional analysis from the Global Burden of Disease Study 2017.
Article in JAAD international, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed.
- Emergence ofJAC-antimicrobial resistance · 2026Article
- Prevalence, aetiology and predisposing factors for tinea capitis amongst pupils in rural communities in the Brong Ahafo Region of Ghana.BMC infectious diseases · 2026Article
- Trichophyton indotineae: Rise, Diagnosis, Treatment, and Future Directions.American journal of clinical dermatology · 2026Review
- Burden of non-invasive fungal infections and antifungal therapy in pediatric primary care settings: FUNGICARE Project.Italian journal of pediatrics · 2026Article
- Long-term spatio-temporal trends in burden of fungal skin diseases in middle-aged and elderly people from 1990 to 2021.PLoS neglected tropical diseases · 2026Article
- Intraspecific Variations and Characteristics of Clinical, Physiological, and Antifungal Susceptibility Profiles of Trichophyton rubrum in Southwest China.Mycopathologia · 2026Article
- Global, regional and national burden of skin and subcutaneous diseases: a systematic analysis of the Global Burden of Disease Study 2021.International health · 2026Article
- Sociodemographic Disparities in Pediatric Dermatological Conditions: Insights From the 2019 Global Burden of Disease Project.Pediatric discovery · 2026Article
- Tinea corporis and tinea cruris incidence, risk factors, and treatments in a cohort of 6.8 million patients with Medicaid, United States.Medical mycology · 2026Article
- Presentations of Cutaneous Disease in Various Skin Pigmentations: Tinea Corporis.HCA healthcare journal of medicine · 2026Article
- Phospholipid-Based Ultraflexible Nanovesicular Gel of Sertaconazole Nitrate for the Treatment of Skin Fungal Infections: Statistical Optimization, In Vitro and Preclinical Assessment.Gels (Basel, Switzerland) · 2025Article
- Epidemiological Trends and Clinical Features ofJournal of Korean medical science · 2025Article
- A Prospective Cohort Study Comparing Microscopy and Culture in the Diagnosis of Superficial Fungal Skin Infections.Medical sciences (Basel, Switzerland) · 2025Article
- Dermatophyte-Selective Imidazole-Thiosemicarbazides: Potent In Vitro Activity AgainstInternational journal of molecular sciences · 2025Article
- Formulation Studies on Microemulsion-Based Polymer Gels Loaded with Voriconazole for the Treatment of Skin Mycoses.Pharmaceutics · 2025Article
- An international survey of recalcitrant and recurrent tinea of the glabrous skin-A potential indicator of antifungal resistance.Journal of the European Academy of Dermatology and Venereology : JEADV · 2025Article
- Risk of Superficial Fungal Infections in WHIM Syndrome.Dermatology and therapy · 2025Article
- Epidemiology and Trends of Cutaneous Fungal Infections (2019-2022) in Israel: A Single Tertiary-Center Study.Journal of fungi (Basel, Switzerland) · 2025Article
- Optimization of LCD-Based 3D Printing for the Development of Clotrimazole-Coated Microneedle Systems.Materials (Basel, Switzerland) · 2025Article
- Skin lesion segmentation with a multiscale input fusion U-Net incorporating Res2-SE and pyramid dilated convolution.Scientific reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionFungal skin diseases are highly prevalent worldwide, but few existing studies focus on the burden of dermatomycoses.
methodsAn analysis of fungal skin disease trends in 2017 in 195 countries worldwide was conducted using the Global Burden of Disease Study database, including prevalence rates, age and sex patterns, and fungal burden, using disability-adjusted life years (DALYs). Age-standardized DALYs were also compared to the sociodemographic index values of all the countries in 2017.
resultsThe age-specific fungal skin disease DALYs in 2017 showed a right-skewed distribution, with a peak between 1 and 5 years of age. The world region with the greatest burden of fungal skin disease was sub-Saharan Africa (DALY rate 89.3 per 100,000 males, 78.42 for females), and the individual country with the greatest DALY rate was Mali (122). The Global Burden of Disease super region with the lowest fungal skin disease burden had high incomes (DALY rate 33.12 per 100,000 males, 30.16 for females), which includes southern Latin America, western Europe, high-income North America, Australasia, and high-income southern Pacific.
conclusionSkin mycoses place a substantial burden on patients worldwide. This burden is the greatest in resource-poor countries, tropical regions, and children between 1 and 5 years of age. DALYs can potentially serve as a purposeful measure for directing health policy resources to improve the global impact of fungal skin disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.